Expression Of CD163 And Beclin1 In Pancreatic Cancer And Their Clinicopathological Significance

Research Background:pancreatic cancer is one of the common malignant tumors of the digestive system,with a poor prognosis.For the atypical early symptom of pancreatic cancer,patients often miss the optimal treatment period before diagnosis,and the vast majority of patients are diagnosed only after the disease has advanced.Due to the difficulty of early diagnosis of pancreatic cancer,many scholars have worked on the research of pancreatic cancer diagnosis methodology with higher sensitivity and specificity for a long time,to improve the probability of early diagnosis,early treatment and further improve the treatment effect.At present,the diagnosis of most pancreatic cancers mainly depends on clinical manifestations,characteristics and the corresponding influential examination results,but there has been no progressive breakthrough.In this study,we explored the expression of CD 163 and Beclin1 in pancreatic cancer tissues and their relationship with clinical parameters,and explored the relationship between CD 163 and Beclin1 in pancreatic cancer and their respective roles in the development of pancreatic cancer,in order to find new target molecules for diagnosis,treatment and prognosis of pancreatic cancer.Objective:to investigate the expression levels and significance of CD163 and Beclin1 proteins in pancreatic cancer tissues,and to explore their relationship with clinicopathological parameters of pancreatic cancer.Methods:Immunohistochemistry was used to detect CD163 and Beclin1 proteins expression level in 43 cases of pancreatic cancer tissues and paired paracancer tissues(2cm away from the edge of the lesion,confirmed by pathology without cancer cell of tissue).Meanwhile,analyzing the expression difference and its relationship with clinical pathological parameters in pancreatic cancer,and analyzing the expression correlation of CD 163 and Beclin1 protein in pancreatic cancer tissues.Results:CD 163 and Beclin1 protein was mainly localized in the cell membrane and cytoplasm and diffusely distributed between the interstitial spaces.The positive expression rate of CD 163 protein in pancreatic cancer tissues was 76.2%,and the positive expression rate in matched tissues adjacent to cancer was 23.8%,and the difference was statistically significant(P<0.05).The positive expression rate of Beclin1 protein in pancreatic cancer tissues was 31.3%,and the positive expression rate in matched tissues adjacent to cancer was 62.7%,and the difference was statistically significant(P<0.05).The expression levels of CD 163 and Beclin1 protein in pancreatic cancer tissues were not significantly correlated with clinicopathological parameters such as gender,age,tumor size,tumor location,local stage,tumor differentiation,node metastasis,nerve invasion and prognosis(P>0.05).The expression levels of CD163 and Beclin1 protein was significantly negatively correlated in pancreatic cancer tissues(R=-0.4944,P<0.05),but there was no correlation between the expression levels of CD 163 and Beclin1 protein of paracancer tissues(R=-0.2172,P=0.1618).Conclusion:Compared with paired paracancer cancer tissues,the expression levels of CD 163 and Beclin1 proteins in pancreatic cancer tissues were up-regulated and down-regulated respectively.In pancreatic cancer tissues,the expression levels of CD 163 and Beclin1 proteins were significantly negatively correlated,but there was no correlation between the expression levels of CD 163 and Beclin1 protein of pancreatic cancer tissues.CD 163 and Beclin1 can probably be detected togther as a marker for diagnosis of pancreatic cancer.